| Drug Name |
Alendronate sodium |
| Drug ID |
BADD_D00065 |
| Description |
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959]. |
| Indications and Usage |
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label]. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB00630
|
| KEGG ID |
D00939
|
| MeSH ID |
D019386
|
| PubChem ID |
6331783
|
| TTD Drug ID |
D09KLR
|
| NDC Product Code |
55111-874; 65862-327; 16714-633; 50090-5677; 65862-268; 0115-1678; 50090-5474; 64980-342; 65862-328; 65862-329; 78206-135; 50090-2322; 64980-340; 60723-205; 63415-0071; 0115-1679; 70954-264; 65691-0056; 0115-1680; 61919-689; 53104-7525; 70518-0033; 16714-631; 17139-400; 0115-1676; 50090-4692; 0054-0282; 13371-111; 60723-207; 16714-632; 0115-1681; 68788-8235; 69097-223; 69097-224; 69543-130; 71205-048; 65372-1134; 61919-729; 64980-341; 67296-1500; 68788-7130; 69543-131; 12658-0568; 50090-3126 |
| UNII |
2UY4M2U3RA
|
| Synonyms |
Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax |
